The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.

The Cigna Group

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco S&P 500 Revenue ETF (Symbol: RWL) where we have detected an approximate $189.7 million dollar inflow -- that's a 3.0% increase week over week in outstanding units (from 57,950,000 to 59,700,000). Among the largest underlying components of RWL, in trading today McKesson Corp (Symbol: MCK) is up about 0.3%, Cencora Inc (Symbol: COR) is up about 0.5%, and The Cigna Group (Symbol: CI) is lower by about 1.2%. For a complete list of holdings, visit the RWL Holdings page » The chart below shows the one year price performance of RWL, versus its 200 day moving average:
Looking at the chart above, RWL's low point in its 52 week range is $86.9713 per share, with $109.0995 as the 52 week high point — that compares with a last trade of $107.95. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Funds Holding AUBN
CATB Insider Buying
STSA Split History
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

RWL, MCK, COR, CI: ETF Inflow Alert

Looking at the universe of stocks we cover at Dividend Channel, on 9/4/25, Home Depot Inc (Symbol: HD), Phibro Animal Health Corp. (Symbol: PAHC), and The Cigna Group (Symbol: CI) will all trade ex-dividend for their respective upcoming dividends. Home Depot Inc will pay its quarterly dividend of $2.30 on 9/18/25, Phibro Animal Health Corp. will pay its quarterly dividend of $0.12 on 9/24/25, and The Cigna Group will pay its quarterly dividend of $1.51 on 9/18/25. As a percentage of HD's recent stock price of $406.92, this dividend works out to approximately 0.57%, so look for shares of Home Depot Inc to trade 0.57% lower — all else being equal — when HD shares open for trading on 9/4/25. Similarly, investors should look for PAHC to open 0.32% lower in price and for CI to open 0.50% lower, all else being equal.
Below are dividend history charts for HD, PAHC, and CI, showing historical dividends prior to the most recent ones declared.
Home Depot Inc (Symbol: HD):
Phibro Animal Health Corp. (Symbol: PAHC):
The Cigna Group (Symbol: CI):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 2.26% for Home Depot Inc, 1.29% for Phibro Animal Health Corp., and 2.01% for The Cigna Group.
Free Report: Top 8%+ Dividends (paid monthly)
In Tuesday trading, Home Depot Inc shares are currently down about 0.1%, Phibro Animal Health Corp. shares are down about 3.6%, and The Cigna Group shares are up about 0.7% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ex-Dividend Reminder: Home Depot, Phibro Animal Health and Cigna

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Dell Technologies Inc (Symbol: DELL), where a total volume of 20,393 contracts has been traded thus far today, a contract volume which is representative of approximately 2.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 46.1% of DELL's average daily trading volume over the past month, of 4.4 million shares. Especially high volume was seen for the $150 strike call option expiring August 29, 2025, with 1,687 contracts trading so far today, representing approximately 168,700 underlying shares of DELL. Below is a chart showing DELL's trailing twelve month trading history, with the $150 strike highlighted in orange:
Generac Holdings Inc (Symbol: GNRC) saw options trading volume of 5,936 contracts, representing approximately 593,600 underlying shares or approximately 45.8% of GNRC's average daily trading volume over the past month, of 1.3 million shares. Especially high volume was seen for the $190 strike put option expiring September 19, 2025, with 2,201 contracts trading so far today, representing approximately 220,100 underlying shares of GNRC. Below is a chart showing GNRC's trailing twelve month trading history, with the $190 strike highlighted in orange:
And The Cigna Group (Symbol: CI) options are showing a volume of 9,752 contracts thus far today. That number of contracts represents approximately 975,200 underlying shares, working out to a sizeable 45.1% of CI's average daily trading volume over the past month, of 2.2 million shares. Particularly high volume was seen for the $340 strike call option expiring December 19, 2025, with 4,208 contracts trading so far today, representing approximately 420,800 underlying shares of CI. Below is a chart showing CI's trailing twelve month trading history, with the $340 strike highlighted in orange:
For the various different available expirations for DELL options, GNRC options, or CI options, visit StockOptionsChannel.com.
Bill Ackman Stock Picks
GDV Insider Buying
RSYS Price Target
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Wednesday Option Activity: DELL, GNRC, CI

Elevance Health, Inc. ELV is taking a bold step in the delivery of primary care by integrating Food as Medicine into its care model. By partnering with the National Association of Community Health Centers (NACHC), the company aims to integrate nutrition into treatment plans, along with prescriptions and diagnostics. This program expands ELV’s existing regional Nourished Well initiative. Elevance Health Foundation will also support NACHC with a six-month Food as Medicine grant.
Through this collaboration, primary care teams at Community Health Centers (CHCs) will be trained to effectively screen and connect Medicaid patients with personalized nutrition support. This includes medically tailored meals, coaching and lifestyle interventions.
As CHC is serving around 34 million Americans, this program aims to reduce food and nutrition insecurities while enhancing chronic disease management and preventive health outcomes. By incorporating these services within the care processes, ELV and NACHC are breaking down barriers to access and establishing a sustainable model for achieving long-term health outcomes.
Looking ahead, ELV, NACHC and CHCs aim to serve as a scalable national model that promotes food-based clinical care by developing a Nutrition Center of Excellence. If a nutrition-focused strategy turns out to be effective, it might open the door to wider acceptance across the U.S. healthcare system. ELV’s individual medical membership rose 5.2% year over year in the second quarter of 2025 to 1.3 million. We expect the metric to rise 0.7% year over year in 2025.
How Are Competitors Faring?
Some of ELV’s competitors in the medical space are Centene Corporation CNC and The Cigna Group CI.
Centene’s high-acuity Medicaid membership grew 6.2% year over year in the second quarter of 2025. Its total membership was around 28 million as of June 30, 2025. Centene’s total revenues rose 22.4% year over year in second-quarter 2025.
Cigna reported 3.2% year-over-year growth in international health customers in the second quarter of 2025. Its total medical customers were around 18 million as of June 30, 2025. Cigna’s total revenues rose 11% year over year in the second quarter of 2025.
Elevance Health’s Price Performance, Valuation & Estimates
Shares of ELV have lost 16.1% in the year-to-date period compared with the industry’s decline of 1%.
Image Source: Zacks Investment Research
From a valuation standpoint, Elevance Health trades at a forward price-to-earnings ratio of 9.62, down from the industry average of 15.08. ELV has a Value Score of A at present.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Elevance Health’s 2025 earnings is pegged at $30.59 per share, implying a 7.4% decline from the year-ago period.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #5 (Strong Sell).
See our %%CTA_TEXT%% report – free today!
7 Best Stocks for the Next 30 Days
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care

At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 06/30/2025 reporting period, and noticed that The Cigna Group (Symbol: CI) was held by 8 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen.
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in CI positions, for this latest batch of 13F filers:
Aggregate Change:
-1,798,192
-$552,930
In terms of shares owned, we count 2 of the above funds having increased existing CI positions from 03/31/2025 to 06/30/2025, with 5 having decreased their positions and 1 new position.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the CI share count in the aggregate among all of the funds which held CI at the 06/30/2025 reporting period (out of the 4,846 we looked at in total). We then compared that number to the sum total of CI shares those same funds held back at the 03/31/2025 period, to see how the aggregate share count held by hedge funds has moved for CI. We found that between these two periods, funds reduced their holdings by 939,548 shares in the aggregate, from 81,604,943 down to 80,665,395 for a share count decline of approximately -1.15%. The overall top three funds holding CI on 06/30/2025 were:
»
Fund
Shares of CI Held
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like The Cigna Group (Symbol: CI).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

See Which Of The Latest 13F Filers Holds CI

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Invesco BuyBack Achievers ETF (Symbol: PKW) where we have detected an approximate $436.3 million dollar outflow -- that's a 24.0% decrease week over week (from 14,520,000 to 11,040,000). Among the largest underlying components of PKW, in trading today The Cigna Group (Symbol: CI) is up about 1.1%, PayPal Holdings Inc (Symbol: PYPL) is up about 2.3%, and CRH plc (Symbol: CRH) is higher by about 2.3%. For a complete list of holdings, visit the PKW Holdings page » The chart below shows the one year price performance of PKW, versus its 200 day moving average:
Looking at the chart above, PKW's low point in its 52 week range is $96.10 per share, with $128.02 as the 52 week high point — that compares with a last trade of $127.26. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Mortgage REITs Hedge Funds Are Selling
RDN Historical Stock Prices
Institutional Holders of PUTW
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy ETF Outflows: PKW, CI, PYPL, CRH

Key Points
Revenue reached $67.2 billion, beating analyst estimates by 7.3% (non-GAAP) and growing 11% year over year.
Adjusted earnings per share (EPS) rose to $7.20, surpassing expectations and EPS increased 7.1% to $7.20, up from $6.72 in the second quarter of 2024.
Evernorth Health Services delivered 17% adjusted revenue growth year over year, but segment profit margins narrowed year over year.
Cigna Group (NYSE:CI), a global health services company offering integrated medical, pharmacy, and specialty care solutions, released its second-quarter earnings on July 31, 2025. The company reported headline financial results (non-GAAP) that outpaced analyst expectations, with revenue climbed to $67.2 billion and adjusted diluted EPS was $7.20. Analysts had expected adjusted EPS (non-GAAP) of $7.16 and revenue of $62,571.45 million. The quarter featured broad-based revenue growth, driven by the Evernorth Health Services platform, though overall profit margins moderated and the company faced shifts in customer mix due to the divestiture of Medicare-related businesses. Overall, the period showed strong execution and ongoing investment in innovation across the enterprise.
Metric
Q2 2025
Q2 2025 Estimate
Q2 2024
Y/Y Change
EPS – Adjusted Diluted (Non-GAAP)
$7.20
$7.16
$6.72
7.1%
Revenue (GAAP)
$67.2 billion
N/A
$60.5 billion
11.1%
Adjusted Revenue (Non-GAAP)
$67.1 billion
N/A
N/A
EPS (GAAP)
$5.71
$5.45
4.8%
SG&A Expense Ratio
5.1%
6.1%
(1.0 pp)
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Business Overview and Strategic Focus
Cigna Group is organized around two primary business platforms: Evernorth Health Services, which provides pharmacy benefit services and specialty care, and Cigna Healthcare, which offers medical insurance plans in the U.S. and globally. By leveraging both platforms, the company aims to deliver integrated solutions across medical, pharmacy, and specialty categories. This dual-structure enables it to address the unique needs of diverse customer groups, from large employers to individual members.
In recent years, Cigna has focused on digital innovation and operational efficiency, investing in artificial intelligence, biosimilars, and customer experience. Key factors for ongoing success include its ability to innovate with digital-first offerings, maintain compliance in a physically and digitally regulated environment, and foster strong partnerships with providers and major clients. Regulatory compliance and risk management remain central to its business, given the industry’s complexity and evolving state and federal requirements.
Quarter Highlights and Key Developments
The quarter was marked by both revenue outperformance (non-GAAP) and significant changes in customer mix. Revenue surged 11%, easily topping consensus estimates by more than $4.56 billion (non-GAAP). Adjusted diluted EPS also edged out expectations, reflecting strong execution in both core and growth segments. Net income (GAAP) was $1.53 billion.
Evernorth Health Services, which includes the company’s broad pharmacy benefit services and specialty care, was the primary engine for this growth. Segment adjusted revenues increased 17% to $57.8 billion, while pre-tax adjusted income rose 5% to $1.70 billion (non-GAAP). Within the pharmacy benefit services product line, Adjusted revenue for Pharmacy Benefit Services grew 20% to $31.954 billion, driven by continued client expansion and new business. The specialty and care services sub-segment—covering complex, high-cost drugs and associated care management—saw adjusted revenues rise 13% to $25.9 billion, highlighting the increased demand for clinically intensive medications. Despite the revenue gains, the Evernorth segment’s pre-tax margin narrowed from 3.3% to 2.9% (non-GAAP, pre-tax).
Cigna Healthcare experienced an 18% decline in adjusted revenues year over year. This drop was expected, as it reflects the divestiture of Medicare businesses to Health Care Services Corporation (the “HCSC transaction”) completed on March 19, 2025. On a comparable basis (excluding the divested businesses), adjusted revenue in Cigna Healthcare rose 7% year over year, driven by stable performance in employer and international insurance offerings. The business saw its pre-tax adjusted profit margin improve slightly to 10.2%, though absolute profit declined 9% due to higher medical costs. A key industry measure, the medical care ratio (MCR), increased from 82.3% to 83.2%. This ratio captures the portion of premiums paid out for member healthcare claims; an increase typically signals higher claim costs relative to premiums earned. Cigna cited “expected higher stop loss medical costs” as the main cause, with management executing on multi-year plans to restore stop-loss product margins.
The company’s customer base saw mixed trends. Total customer relationships stood at 182.2 million as of June 30, 2025. Excluding the impact of the HCSC transaction, total customer relationships increased 2% from December 2024, but this reflects the removal of Medicare customers following the business sale. Pharmacy customer counts grew 3% from December 2024, reaching 121.9 million as of June 30, 2025. The medical customer base declined to 18.0 million, but remained roughly stable after adjusting for divestitures. even as major client contracts and portfolio changes impact short-term customer numbers.
Cigna also posted notable improvements in cost efficiency, as reflected by a decrease in the adjusted SG&A expense ratio to 4.9% from 6.0% (non-GAAP), reducing its Selling, General & Administrative (SG&A) expense ratio (GAAP) to 5.1% from 6.1%. reflecting a shift in business mix and strong revenue growth. On the capital deployment front, the company reported $2.6 billion in share repurchases year to date through May 1, 2025, and has signaled a continued focus on returning excess capital to shareholders, strategic M&A, and internal investment.
The period also saw continued emphasis on innovation. The company expanded digital engagement initiatives, including programs such as EncircleRx, inReachRx, and InGuide—tools designed to manage the costs and patient experience for GLP-1 prescription drugs, which are increasingly used for diabetes and weight management. Such clinical support models are aimed at both improving patient outcomes and helping corporate clients control pharmacy spending, particularly with high-cost drug trends growing rapidly. Notably, CEO David Cordani highlighted the “meaningful value” delivered through listening, adapting, and innovating to meet client and patient needs.
The divestiture affected year-over-year comparisons by reducing both reported revenue and customer counts within Cigna Healthcare. The company emphasized that apart from this portfolio shift, underlying fundamentals and customer retention remained stable, supported by a multi-year focus on capital discipline, innovation, and regulatory compliance.
Looking Forward: Guidance and Key Watch Areas
Leadership reaffirmed guidance for FY2025, projecting adjusted income from operations of at least $29.60 per share. At the segment level, Evernorth is expected to deliver at least $7.2 billion in pre-tax adjusted income from operations in FY2025, while Cigna Healthcare adjusted income from operations, pre-tax, is set for at least $4.125 billion in FY2025. The company anticipates a medical care ratio in Cigna Healthcare of 83.2% to 84.2% in FY2025. These figures incorporate the impact of additional share repurchases and planned dividend payments over the remainder of FY2025.
Management stressed that, despite exceeding expectations (non-GAAP), it chose not to raise full-year guidance, pointing to ongoing expense pressures—especially in stop loss insurance and rising medical costs. Investors will want to keep an eye on margin trends in both Evernorth and Cigna Healthcare, as well as the broader impacts of industry regulation, client concentration, and innovative product launches in high-cost drug management. Ongoing legislative activity in states such as Arkansas, targeting regulations of pharmacy benefit managers (PBMs) and specialty pharmacies, is also a key area to monitor given the potential business model impact.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of July 29, 2025
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Cigna (CI) Q2 Revenue Jumps 11%

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. However, when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.
Cash flow can come from bond interest, interest from other types of investments, and, of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures a dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.
Cigna (CI) is headquartered in Bloomfield, and is in the Medical sector. The stock has seen a price change of -3.17% since the start of the year. The health insurer is paying out a dividend of $1.51 per share at the moment, with a dividend yield of 2.26% compared to the Medical - HMOs industry's yield of 0.74% and the S&P 500's yield of 1.48%.
Looking at dividend growth, the company's current annualized dividend of $6.04 is up 7.9% from last year. Over the last 5 years, Cigna has increased its dividend 5 times on a year-over-year basis for an average annual increase of 81.54%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Cigna's current payout ratio is 22%, meaning it paid out 22% of its trailing 12-month EPS as dividend.
Earnings growth looks solid for CI for this fiscal year. The Zacks Consensus Estimate for 2025 is $29.68 per share, representing a year-over-year earnings growth rate of 8.60%.
From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. However, not all companies offer a quarterly payout.
High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. During periods of rising interest rates, income investors must be mindful that high-yielding stocks tend to struggle. With that in mind, CI is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of #3 (Hold).
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Why Cigna (CI) is a Great Dividend Stock Right Now

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. The Cigna Group (Symbol: CI) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.
But making The Cigna Group an even more interesting and timely stock to look at, is the fact that in trading on Wednesday, shares of CI entered into oversold territory, changing hands as low as $295.50 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of The Cigna Group, the RSI reading has hit 29.7 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 51.9. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, CI's recent annualized dividend of 5.6/share (currently paid in quarterly installments) works out to an annual yield of 1.80% based upon the recent $311.37 share price.
A bullish investor could look at CI's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on CI is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.
Free Report: Top 8%+ Dividends (paid monthly)
QBTS Options Chain
SPE Average Annual Return
UTRS Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Relative Strength Alert For The Cigna Group

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Boston Beer Co Inc (Symbol: SAM), where a total of 1,437 contracts have traded so far, representing approximately 143,700 underlying shares. That amounts to about 52.8% of SAM's average daily trading volume over the past month of 271,915 shares. Especially high volume was seen for the $170 strike call option expiring August 15, 2025, with 1,350 contracts trading so far today, representing approximately 135,000 underlying shares of SAM. Below is a chart showing SAM's trailing twelve month trading history, with the $170 strike highlighted in orange:
The Cigna Group (Symbol: CI) saw options trading volume of 8,014 contracts, representing approximately 801,400 underlying shares or approximately 51.6% of CI's average daily trading volume over the past month, of 1.6 million shares. Particularly high volume was seen for the $275 strike put option expiring August 01, 2025, with 1,172 contracts trading so far today, representing approximately 117,200 underlying shares of CI. Below is a chart showing CI's trailing twelve month trading history, with the $275 strike highlighted in orange:
And Liquidia Corp (Symbol: LQDA) options are showing a volume of 12,620 contracts thus far today. That number of contracts represents approximately 1.3 million underlying shares, working out to a sizeable 51.6% of LQDA's average daily trading volume over the past month, of 2.4 million shares. Especially high volume was seen for the $17.50 strike put option expiring November 21, 2025, with 5,030 contracts trading so far today, representing approximately 503,000 underlying shares of LQDA. Below is a chart showing LQDA's trailing twelve month trading history, with the $17.50 strike highlighted in orange:
For the various different available expirations for SAM options, CI options, or LQDA options, visit StockOptionsChannel.com.
Also see:
CSWC Stock Predictions
GAL Videos
Funds Holding VNR
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	27.66 23.75
Price/Sales	0.38 3.01
P/B	2.23 2.20
P/FCF	10.60 18.30

Indicator	TTM Median
ROE	8.25 25.41
ROA	2.21 6.00
ROI	4.79 9.66
Net Worth	94.93 0.20
Quick Ratio	0.00 1.71
Current Ratio	0.65 2.83

Indicator	TTM Median
Net Profit Margin	1.39 10.25
Operating Margin	3.81 14.24
Gross Margin	84.36 68.59
Return on tangible equity	0.00 53.53

Indicator	TTM Median
EPS	6.74 0.37
EPS Forecast	6.39 0.37
Revenue	65.65B 16.00M
Gross Profit	55.48B —
EBITDA	2.82B —

The Cigna Group

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue